why does semaglutide make you constipated Constipation: Causes & Relief Tips Wegovy constipation: causes, relief, and

Description

Semaglutide, a glucagon-like peptide (GLP-1) analog, that mimics the action of GLP-1, a hormone produced in the small intestine

If youre unsure, check the patient leaflet or ask your healthcare provider

3 The safety of retatrutide So far, retatrutide looks broadly safe, with side effects that mirror existing GLP-1 medications

This suggests FDA labeling may include enhanced indications for: BMI 35 with history of heart attack, stroke, or coronary artery disease High-risk cardiovascular patients needing maximum weight reduction Medical Contraindications: Who Cannot Take Retatrutide Absolute Contraindications (Definite Disqualification) Personal or Family History of Medullary Thyroid Cancer: Retatrutide (like all GLP-1 medications) carries theoretical MTC risk Anyone with personal or family history cannot take it This is a black box warning that will appear on FDA label Multiple Endocrine Neoplasia Syndrome Type 2 (MEN2): Genetic condition increasing thyroid cancer risk Absolute contraindication for all GLP-1/GIP/glucagon agonists Pregnancy and Breastfeeding: Retatrutide not studied in pregnant or breastfeeding women Animal studies showed potential fetal harm Must use contraception during treatment Stop medication 2 months before attempting pregnancy Recent Bariatric Surgery: TRIUMPH trials excluded patients with bariatric surgery in past 18 months Medication may not be appropriate post-surgery Discuss timing with bariatric surgeon and endocrinologist Relative Contraindications (Case-by-Case Basis) History of Pancreatitis: GLP-1 medications may increase pancreatitis risk Prior pancreatitis = high caution Some doctors won't prescribe, others will with close monitoring Severe Gastrointestinal Disease: Gastroparesis (delayed gastric emptying) Inflammatory bowel disease (Crohn's, ulcerative colitis) Severe GERD Retatrutide slows gastric emptying could worsen these conditions Diabetic Retinopathy (for diabetics): Rapid glucose improvement can temporarily worsen retinopathy Requires ophthalmology clearance before starting Close monitoring during treatment Severe Kidney Disease: TRIUMPH trials excluded eGFR 75) may require careful consideration due to: Higher dysesthesia risk Multiple medications (drug interactions) Frailty concerns with rapid weight loss Pediatric Population: Not studied